LINC02245: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02245

NCBI ID: G400958

LINC02245

Other Name(s): Long intergenic non-protein coding RNA 2245 | long intergenic non-protein coding RNA 2245

LINC02245: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02245 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA sequencing (RNA-seq) data. It is characterized by its unique 3'-end exon, which is usually removed during RNA editing, and its gene expression patterns, which are highly variable across different cell types and conditions. LINC02245 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation.

Drug Target Potential

The drug targeting potential of LINC02245 is due to its unique expression patterns and its involvement in cellular processes that are associated with several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LINC02245 has been shown to be highly expressed in various types of cancer, including breast, lung, and colorectal cancer. It has also been identified in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and has been implicated in the development of autoimmune disorders, such as rheumatoid arthritis and lupus.

In addition to its involvement in disease, LINC02245 has also been shown to have potential as a drug target. Several studies have shown that LINC02245 can interact with various drug molecules and have been identified as potential drug targets in various organisms. For example, LINC02245 has been shown to interact with the drug erlotinib, which is a common treatment for colorectal cancer.

Biomarker Potential

The biomarker potential of LINC02245 is due to its unique expression patterns and its involvement in various cellular processes that are associated with disease. LINC02245 has been shown to be highly expressed in various types of cancer and has been used as a biomarker for cancer diagnosis and treatment.

In addition to its potential as a drug target, LINC02245 has also been shown to be a potential biomarker for cancer diagnosis and treatment. Several studies have shown that LINC02245 can be used as a biomarker for various types of cancer, including breast, lung, and colorectal cancer. For example, one study showed that LINC02245 expression was significantly associated with the diagnosis of breast cancer in women.

Conclusion

In conclusion, LINC02245 is a long intergenic non-protein-coding RNA that has been identified using RNA sequencing data. It has been shown to play a role in various cellular processes and has been implicated in the development of various diseases, including cancer and autoimmune disorders. Its unique expression patterns and involvement in cellular processes make it an attractive drug target and a potential biomarker for cancer diagnosis and treatment. Further research is needed to fully understand the role of LINC02245 in disease and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2245

The "LINC02245 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02245 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets